Diagnostic HYBRIDS Releases D3 Ultra 8 DFA Respiratory Virus Screening & ID Kit in Canada
Diagnostic HYBRIDS announces the release of its D3(R) Ultra 8(TM) DFA Respiratory Virus Screening & Identification Kit for the Canadian market. Ultra 8 is the only commercially available monoclonal antibody blend that detects and identifies eight major respiratory viruses – including human metapneumovirus – in direct patient specimens and cell culture by immunofluorescence. Direct specimen results are available in as little as 15-30 minutes. When combined with the patented Diagnostic HYBRIDS cell culture systems (R-Mix(TM) and R-Mix Too(TM) Mixed FreshCells(TM)), multi-virus results can be obtained in as little as 24 hours for influenza A and B, and less than 48 hours for MPV, RSV, Adenovirus, and Parainfluenza 1, 2, and 3.
According to Ron Lollar, Senior Director of Product Management & Marketing for DHI, “Metapneumovirus infection is especially prevalent in infants and elderly patients, but is often indistinguishable from RSV infection, making it difficult to prevent cross-infections through accurate patient isolation and cohorting. The addition of antibodies against metapneumovirus antigens to our premier D3 Respiratory Virus Screening and Identification Kit allows laboratories to identify the eight major respiratory viruses in a clinically relevant time frame, allowing physicians to make decisions based on a definitive diagnosis instead of on symptoms alone.”
The D3 Ultra 8 DFA Respiratory Virus Screening & Identification Kit is a major addition to Diagnostic HYBRIDS’ rapid respiratory virus testing system. The system includes the Flocked Swab/UTM for specimen collection and transport, the R-Mix(TM) and R-Mix Too(TM) mixed cell culture systems which allow for the rapid isolation of influenza A and B, MPV, RSV, Adenovirus and Parainfluenza 1, 2, and 3, and now the D3 Ultra 8 DFA Respiratory Virus Screening & Identification Kit. The complete respiratory testing system including the new D3 Ultra 8 DFA kit is available in select international markets.
About Diagnostic HYBRIDS
Diagnostic HYBRIDS invents, develops, manufactures, and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company is certified to ISO 13485 standards (2003) and manufactures live continuous and primary cell cultures for clinical diagnostics and pharmacology assays from its headquarters in Athens, OH. Diagnostic HYBRIDS was named one of the 500 Fastest Growing Companies in America in 2004 and 2005 by Inc. Magazine. The company is a pillar member of BioOhio, a statewide organization of bioscience companies accelerating the bioscience and healthcare economy in Ohio. For more information, please visit www.dhiusa.com.
Note to editors: If the “3″ in “D3″ appears to be a full-size character, please note that it should be superscript.